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Abstract 
Background: MicroRNAs (miRNAs) play multiple roles in tumor biology [1]. 
Interestingly, reports from multiple groups suggest that miRNA targets may be coupled 
through competitive stoichiometric sequestration [2]. Specifically, computational models 
predicted [3, 4] and experimental assays confirmed [5, 6] that miRNA activity is 
dependent on miRNA target abundance, and consequently, changes to the abundance 
of some miRNA targets lead to changes to the regulation and abundance of their other 
targets. The resulting indirect regulatory influence between miRNA targets resembles 
competition and has been dubbed competitive endogenous RNA (ceRNA) [5, 7, 8]. 
Recent studies have questioned the physiological relevance of ceRNA interactions [9], 
researchers ability to accurately predict these interactions [10], and the number of 
genes that are impacted by ceRNA interactions in specific cellular contexts [11]. 
Results: To address these concerns, we reverse engineered ceRNA networks 
(ceRNETs) in breast and prostate adenocarcinomas using context-specific TCGA 
profiles [12-14], and tested whether ceRNA interactions can predict the effects of RNAi-
mediated gene silencing perturbations in PC3 and MCF7 cells. Our results, based on 
tests of thousands of inferred ceRNA interactions that are predicted to alter hundreds of 
cancer genes in each of the two tumor contexts, confirmed statistically significant effects 
for half of the predicted targets.  
Conclusions: Our results suggest that the expression of a significant fraction of cancer 
genes may be regulated by ceRNA interactions in each of the two tumor contexts. 
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Background 
Identifying regulatory interactions that mediate the effects of genomic alterations is a 
necessary step for interpreting the function of trans-acting variants in complex diseases, 
including cancer [15, 16]. Among these, miRNA dysregulation, arising from alterations 
targeting their transcriptional [17] or biogenesis regulators [18], plays an established 
role in tumorigenesis [1]. Recently, multiple groups have reported on gene products that 
modulate miRNA activity [5-7, 19-26], including RNA species that can alter the 
abundance of other RNAs in trans through ceRNA interactions. These studies show that 
targets of the same miRNAs are coupled and that up- or down-regulation of one target 
may alter the expression of other cognate targets by sequestering or releasing their 
shared miRNA molecules, respectively (Figure 1A).  
Since the discovery of ceRNA regulation in human cells [21, 22] multiple reports 
questioned the physiological relevance of ceRNA interactions, researcher’s ability to 
predict them, and the number of genes that are affected in each context [9-11]. To 
address these concerns, we proceeded to test genome-wide ceRNA predictions made 
by the information-theoretic Hermes algorithm [5]. For the sake of generality, we 
performed this analysis in two distinct tumor contexts, using a set of large-scale and 
high-throughput shRNA-mediated perturbation assays in model cell lines assembled by 
the Library of Integrated Network-based Cellular Signatures (LINCS) [14]. Specifically, 
we inferred ceRNETs using TCGA profiles of prostate and breast adenocarcinomas and 
tested them using a LINCS compendium of perturbation profiles, representative of the 
shRNA-mediated silencing of >3,000 genes in PC3 and MCF7 cells [12-14]. We 
propose that the high validation rates of these assays can inform on the accuracy of 
computational predictions, and will help estimate the number of genes that are 
modulated by ceRNA in representative tumor contexts. 
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Methods and Results 
Inference method  
We used an extended version of the Hermes algorithm, which we had previously 
introduced to discover and validate glioma-specific ceRNAs [5], to systematically 
discover ceRNA interactions in prostate (PRAD) and breast (BRCA) adenocarcinomas, 
using matched miRNA and mRNA expression profiles of the corresponding TCGA 
cohorts. While the ceRNA inference component of the algorithm was unchanged, the 
new algorithm also supports the identification of the specific miRNAs that mediate each 
interaction (mediators); these miRNAs are predicted to target both mRNAs in a ceRNA 
interaction, and their activity is affected by modulation of target mRNA abundance. This 
extension is useful for generating more specific hypotheses for future functional testing.  
We note that Hermes-inferred ceRNA interactions are independent of the co-expression 
of coupled mRNAs; rather, they are based on assessing whether the abundance of one 
mRNA species modulates abundance of the other (and vice-versa), via their shared 
miRNA program. This assessment is based on the statistical significance of the mutual 
information between the abundance of one mRNA species and one or more miRNA, 
given the abundance of another mRNA targeted by the same miRNAs. We note that a 
majority of predicted ceRNA interactions involved mRNAs that are not significantly co-
expressed, and co-expression did not implicate genes as ceRNA interacting partners. 
Hermes predicts ceRNA-coupling between two mRNAs based on the relative size of 
their shared miRNA regulatory program, as predicted by the Cupid algorithm [5], and 
the conditional mutual information between one of the mRNAs and each of their shared 
miRNAs, given the other mRNA. Namely, given genes Ti and Tj, and the set of miRNAs 
that regulate them Π𝑚𝑖𝑅(𝑇𝑖) and Π𝑚𝑖𝑅(𝑇𝑗), their shared program is identified by taking 
the intersection Π𝑚𝑖𝑅(𝑇i; 𝑇j) = Π𝑚𝑖𝑅(𝑇𝑖) ∩ Π𝑚𝑖𝑅(𝑇𝑗). First, Hermes tests that the size of 
Π𝑚𝑖𝑅(𝑇𝑖; 𝑇𝑗) relative to the sizes of the individual programs is statistically significant at 
FDR < 0.01 by Fisher’s exact test (FET). Then, Hermes evaluates the statistical 
significance 𝑝𝑘𝑖𝑗(p-value) of the test 𝐶𝑀𝐼[𝑚𝑖𝑅𝑘; 𝑇𝑖,|𝑇𝑗] > 𝑀𝐼[𝑚𝑖𝑅𝑘; 𝑇𝑖], where CMI and MI 
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stand for conditional mutual information and mutual information respectively, and the 
variables indicate the expression of the corresponding RNA species [5]. 
The CMI is estimated using an adaptive partitioning algorithm [27] by first iteratively 
partitioning the 3-dimentional expression space evenly into 8 partitions per iteration until 
partitions are balanced (p>0.05 by Chi-squared test), and then summing up CMI across 
partitions. P-values for each triplet are computed based on a null-hypothesis where the 
candidate modulator’s expression (𝑇𝑗 ) is shuffled 1,000 times, thus preserving the 
pairwise mutual information between miRNA and target. Final significance across the 
entire set of miRNA mediators is computed using Fisher’s method to integrate both 
regulatory directions, i.e. Ti affecting miRk regulation of Tj as well as Tj affecting miRk 
regulation of Tj, for all miRNA mediators  Π𝑚𝑖𝑅(𝑇i; 𝑇j).  Specifically, 𝑋
2 =
−2 ∑ ln ( 𝑝𝑘𝑖𝑗, 𝑝𝑘𝑗𝑖
𝑁
𝑘=1 ) is computed and used to estimate a significance p-value for the 
entire program. Note that 𝑋2  follows a Chi-square distribution, with 4𝑁  degrees of 
freedom, where 𝑁  is the number of miRNAs in the shared program. Finally, only 
predictions passing significance of FDR<1E-3 are selected. Note that selected 
predictions by Hermes have been previously validated in glioblastoma cell lines [5]. In 
addition, the presence of transcripts with alternative 3’ UTRs is expected to reduce the 
sensitivity of prediction.  
In order to identify miRNA mediators in addition to ceRNA interactions, we modified 
Hermes to perform greedy addition of miRNA mediators and to optimize the combined 
p-value for each predicted interaction. Namely, for each candidate interaction, we 
searched for the minimum combined p-value through the greedy forward inclusion of 
individual miRNAs. Additional miRNAs were included as candidate mediators only if 
they improve the joint p-value, as estimated using Fisher’s method. MiRNAs failing to 
improve the joint p-value lack functional evidence for mediating the interaction and were 
thus excluded from the analysis. 
Inferred ceRNETs 
We used Hermes to construct ceRNETs using matched TCGA gene and miRNA 
expression profiles of breast (BRCA) and prostate (PRAD) adenocarcinomas. For 
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PRAD, this included data from 140 samples, representing 23,614 genes and 367 
miRNAs[28]; while for BRCA, we used 207 samples, representing 18,748 genes and 
524 miRNAs[29]. Predicted ceRNA networks included 476,456 and 447,011 
interactions, for the PRAD and BRCA ceRNETs, respectively; see Tables S1-2, where 
each ceRNA interaction is defined by two RNAs and the miRNAs that couple them. 
Due to their size, experimental validation of reverse-engineered networks is often 
challenging. Consequently, validation is generally performed only on a handful of 
interactions [30, 31] or on small subnetworks [32, 33]. To validate our inferred 
interactions on a more realistic scale, we used a large collection of shRNA-mediated 
silencing assays in the Library of Integrated Network-based Cellular Signatures (LINCS) 
database [14]. 
The LINCS database 
The LINCS database includes Luminex-based multiplexed assays to measure the 
expression of 1,171 genes (L1000) in response to a variety of perturbations. Selected 
perturbations include shRNA-mediated silencing (in triplicate) of 1,845 genes 
participating in ceRNA interactions, in both BRCA (MCF7) and PRAD (PC3) cell lines 
(Tables S3 and S4). Gene expression was measured using the L1000 assay at two time 
points (96h and 144h), following each perturbation. To achieve adequate statistical 
power, we limited our tests to genes with six or more silenced Hermes-inferred ceRNA 
regulators. In total, we evaluated predicted ceRNA targeting of 405 genes (of which 365 
were validated at 96h and 398 at 144h) in MCF7 cells and 419 genes (of which 363 
were validated at 96h and 376 at 144h) in PC3 cells. 
In LINCS perturbation assays, while some data points are missing due to quality control 
metrics, the expression of most genes was profiled in triplicates at both 96h and 144h 
after shRNA transduction. On average, 3.3 unique shRNA hairpins were used to silence 
each of 1,845 breast and prostate oncogenes and tumor suppressors (cancer genes) in 
our networks. By definition, for each interaction, the ceRNA regulator is the one targeted 
by the shRNA perturbation and the ceRNA target is the one profiled after silencing to 
determine any interaction mediated change. Fold-change for each target, in response to 
the silencing of one of its regulators, was estimated by averaging across all shRNA 
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hairpins targeting this regulator. The identities of the specific shRNA hairpins, 
regulators, and targets are provided in Table S5.  
In total, 9,055 and 9,800 predicted BRCA interactions were tested in MCF7 cells at 96h 
and 144h after shRNA-mediated silencing, respectively. Similarly, 8,858 and 10,213 
predicted PRAD interactions were tested in PC3 cells at 96h and 144h after silencing, 
respectively. Due to the small number of replicates, it is not possible to evaluate the 
statistical significance of individual predicted interactions. Instead, we evaluated the 
average effects of all ceRNA regulators in the list of silenced genes on the expression of 
a given ceRNA target. Average fold changes and associated standard errors were 
computed by comparing to non-targeting controls, at each time point, and in each 
relevant cellular context. Tables S3 and S4 provide mRNA expression fold change 
measurements following shRNA-mediated perturbation of breast and prostate cancer 
genes in MCF7 and PC3, respectively, based on the LINCS perturbation assays. 
The size of this dataset allows for rigorous controls that avoid bias due to gene 
expression variability and off-target effects of RNAi-mediated perturbations. To estimate 
the statistical significance of target responses to gene perturbations, we examined fold 
change in target expression following silencing of its predicted regulator, as well as the 
effect of silencing a specific regulator across all of its inferred targets. For the latter, we 
associated each candidate target with a rank vector representing its percentile ranked 
relative fold-change at a specific time point following each gene silencing perturbation. 
We then ranked expression fold-changes of all profiled genes at a specific time point 
following silencing of any given gene and compared ranks across different 
perturbations. In this way, each candidate target was associated with a rank vector, 
representing its relative fold-change following each perturbation. Considering each 
target in isolation, we compared its response to perturbations of its predicted regulators 
as well as its response to shRNA-mediated silencing of other genes. Mann–Whitney U 
test was used to determine whether the rank of a target following silencing of its 
predicted regulators was lower than that following silencing of other genes. 
Specifically, Fold change measurements for up to 1,171 genes in response to a given 
perturbation allowed ranking of the profiled genes based on the strength of the 
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response. First, we assigned significance to the response of a gene to the silencing of 
its predicted regulators by comparing the set of its scores associated with perturbations 
of predicted regulators to the scores of all other genes, i.e. the gene’s ranks following 
silencing of its predicted regulators vs. its ranks following silencing of all other genes. 
Then we used a Mann-Whitney test to determine whether the ranks of a target after 
silencing of its regulators was significantly lower than its ranks following silencing of all 
other genes. Given the number of gene perturbations (up to 1,171 gene silencing 
experiments), the two sets of ranks were expected to be normally distributed and can be 
approximated by a z-score and a corresponding p value. On average, for each target 
gene, the number of perturbations targeting its regulators was 1% of the total number of 
perturbations tested. 
Predicted cancer genes are affected by silencing of their ceRNA regulators 
Figures 1B-C describe the average response of a target at a given time point to 
silencing of all of its tested regulators. Standard error was computed using standard 
error propagation techniques, i.e., the standard error was estimated as√∑ σ𝑖
2𝑁
𝑖=1 , where σ𝑖 
is the standard deviation of each individual silencing experiment and 𝑁 is the number of 
tested regulators. Figures 2 and 3 show the responses of targets described in 
Figure 1B-C to perturbations of both predicted regulators and non-regulators in MCF7 
and PC3. For perturbations of regulators, we provided p values that describe the 
significance of target responses. An evaluation of all individual interactions and overall 
responses of each target in both networks is provided in Table S5. When comparing 
responses of ceRNA targets to controls, as described in Figure 1B-C, we randomly 
assembled control sets composed of as many non-ceRNA regulators as the number of 
ceRNA regulators for each target. We then calculated the average fold change and the 
error-propagated standard error after silencing each of non-ceRNA regulator, and 
estimated the significance of fold changes using a two-tailed rank-sum test. This 
process was repeated 1,000 times to obtain averaged fold changes, propagated 
standard errors, and averaged p values based on the negative controls. 
Results from these assays confirmed that Hermes predictions are highly enriched in 
bona fide ceRNA interactions in both BRCA and PRAD and that these interactions may 
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affect the activity of key cancer genes. For instance, 10 established driver cancer genes 
in BRCA (BCL2, CCND1, CCNE2, CDC42, CDKN1B, EGR1, FOS, HMGA2, NRAS and 
RB1) and PRAD (BCL2, CDKN1B, EGR1, HIF1A, JUN, KIT, MAP4K4, MYC, RB1 and 
STAT3) were significantly down regulated when their Hermes-inferred ceRNAs were 
silenced but were unaffected by silencing of negative control genes (i.e., genes not 
predicted as their cognate ceRNA regulators); see Figures 1B-C, 2 and 3.  In total, 69% 
and 62% of Hermes-inferred targets were significantly down-regulated (p < 0.05 by U 
test) following shRNA-mediated silencing of their Hermes-inferred ceRNAs in MCF7 and 
PC3, respectively, at least at one time point; see Figure 4 and Table S5. Fold-change 
and p-values were measured by comparing average differential expression of a gene 
following shRNA-mediated silencing of its inferred ceRNA regulators, compared to 
silencing of all other genes not predicted to be ceRNA targets of these regulators. This 
guaranteed the most unbiased selection of negative control assays possible. Moreover, 
our efforts to control for specific effects that could potentially bias this comparison—
including shRNA off-target effects and outliers—reaffirmed analysis results. 
Accounting for systematic biases 
To ensure that comparisons of target responses to predicted regulators and non-
regulators are free of bias, we repeated the analysis presented in Figure 4 for MCF7 
and PC3 after controlling several properties. These included re-analyses after (1) 
eliminating outlier responders, i.e. ceRNA interactions associated with the most 
significant ceRNA-validating responses; (2) eliminating shRNAs that can act as human 
miRNAs[34] and produce off-target effects; and after accounting for (3) 3’ UTR length 
and (4) CG content, (5) RMA-normalized expression, (6) expression variability, and (7) 
expression correlation with the predicted target. Results are presented in Figure S1 and 
suggest that accounting for these potential biases had relatively little effect on the 
number of targets that were found to be significantly down regulated by silencing their 
predicted regulators. We note that the average gene expression change across all 
interactions in LINCS is 1.0. 
When eliminating outliers we removed predicted ceRNA interactions where the inducing 
effects were greater than Q1-1.5*STD by percentile rank from the analysis. By 
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discarding the strongest ceRNA-like effects, we eliminated any chance that the test may 
be biased by a few outlier events. To eliminate potential off-target effects caused by 
miRNA-like behavior, we eliminated all shRNAs whose 7-base seed subsequence (2nd 
to 8th position) matched miRBase human miRNA seeds. To study the effects 3’ UTR 
length and composition, we binned all potential ceRNA regulators including predicted 
regulators and controls; 3’ UTRs were binned by either length using 25-base offsets or 
by GC content in 0.001 intervals. Length and content were studied independently. When 
comparing ceRNA interactions to non-interactions (controls), both were taken from 
corresponding bins. To study the effects of expression magnitude, we averaged MCF7 
and PC3 gene RMA-normalized expression across 213 MCF7 and 64 PC3 experiments 
deposited in Gene Expression Atlas [35], binned at 0.01 intervals. Expression variability 
describes median absolute deviation, binned at 0.001 intervals. Expression correlation 
was measured using Spearman correlation with the expression profile of the target, 
binned at 0.01 intervals.  
Integrative Statistical Evaluation 
To evaluate the significance of all tested interactions at each time point in both cell 
lines, we used a one-sample Kolmogorov-Smirnov test [36]. This normality test 
evaluates whether z scores obtained from fold-change rank comparisons follow a 
standard normal distribution with µ = 0 and σ = 1, thus assigning significance against 
the null hypothesis that z scores are selected at random. We ranked targets based on z 
scores and calculated the expected p value when assuming that z scores were drawn 
from a standard normal distribution. The result is p-value estimates for each time point 
for each of the two cell lines, taken in aggregate across all tested interactions. The 
result suggested that ceRNA interactions, even when disregarding all other regulatory 
modalities, are highly predictive of assay observations: p<2e-96 and p<1e-123 for 
MCF7 at 96H and 144H, and p<6e-84 and p<3e-96 for PC3 at 96H and 144H, 
respectively. We did not aggregate across time points and cell lines to avoid statistical 
dependence that is sure to result from using the same shRNAs in multiple assays. 
In MCF7 cells, of the 365 and 398 genes that could be tested at 96h and 144h following 
silencing of their predicted ceRNA regulators, respectively, the vast majority (i.e., 337 
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and 363) were down regulated. Of these, 181 and 202 were significantly down regulated 
(p < 0.05); only 28 and 35 genes were up regulated, none significantly. Similarly, for 
PC3 cells, 319/363 and 336/376 were down regulated (at 96h and 144h, respectively). 
Of these, 170 and 174 were significantly downregulated (p < 0.05); only 44 and 40 were 
up regulated, none significantly.  
In total, 342 tested ceRNA targets were significantly down regulated in at least one 
assay, at an average of more than 2 assays per target, while none were significantly up-
regulated (p < 0.05). In aggregate, down-regulation of predicted ceRNA targets was 
highly significant (p ≤ 6.0E-84 for each time point and cell line). This analysis constitutes 
the largest scale validation of a regulatory network to date and suggests that hundreds 
of cancer genes may be altered through competition for miRNA regulation in BRCA and 
PRAD. Critically, these results are not merely a reflection of intrinsic coupling of gene 
expression in cellular systems. Indeed, equivalent numbers of interactions selected at 
random from non-predicted ceRNAs produced no statistically significant trends. In total, 
nearly 50% (50% in MCF7 and 47% in PC3) of all predicted targets were significantly 
down regulated by shRNA-mediated silencing of their predicted ceRNA. We note that 
when considering individual interactions, 31% of targets were down regulated following 
silencing of their predicted regulators.  
Comparisons with other ceRNA prediction methods 
To test whether Hermes predictions are uniquely enriched for down regulation in LINCS 
data, we used LINCS assays to test predictions by MuTaME [23] and cefinder [37]. Our 
results suggest that while Hermes significantly outperformed both methods (Figure S2), 
MuTaME and cefinder predictions are significantly enriched in down regulated genes 
following shRNA-mediated silencing of their regulators.  
We used all available predictions by cefinder and MuTaME for our comparison. cefinder 
scores ceRNA interactions based on the number of miRNA binding sites from the 
common miRNA program between the ceRNA target X and ceRNA regulator Y; only the 
top 50 ceRNA regulators are predicted for each ceRNA target, and Y->X doesn't imply 
X->Y because X might not be in the top 50 genes of Y. MuTaME provided 136 PTEN-
regulating ceRNAs (of which 135 were targeted by LINCS) and the standalone program 
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is not downloadable. Ala et al. used MuTaME to predict DICER1-regulating ceRNAs[3], 
but only 4 genes that were predicted to interact with DICER1 were targeted in LINCS. 
Consequently, we chose to compare the three methods when predicting PTEN 
regulators and targets (predictions by MuTaME are bidirectional), but genome-wide 
comparisons were made between Hermes and cefinder only. The comparisons suggest 
that Hermes outperforms MuTaME and cefinder when predicting PTEN targets and 
regulators (Figure S2), and it significantly outperforms cefinder on genome wide tests 
(Figure S3).  
Discussion 
We proposed and re-implemented Hermes, a highly-selective context-specific method 
for predicting ceRNA interactions[5]. When analyzing TCGA profiles of prostate [38] and 
breast [39] adenocarcinomas Hermes inferred nearly 500K ceRNA interactions in each 
of the two tumor types.  
In total, Hermes produced expression-based evidence for the regulation of over 5,000 
genes by ceRNA interactions. Conclusions from perturbation assays that tested 
hundreds of these genes as potential targets are that half of them are dysregulated by 
targeting their Hermes-inferred ceRNA regulators. Put together, the results suggest that 
thousands of genes can be dysregulated be ceRNA interactions in each of the two 
contexts through exogenous perturbations or through genomic alterations that target 
their ceRNA regulators. 
Conclusions 
Computational evidence in conjunction with high-throughput biochemical assays, 
suggest that ceRNA regulation is the norm and not an exception in cancer cells. While 
ceRNA interactions can be easily detected and validated in extreme cases—as in 
MYCN-amplified neuroblastomas [6] or binding-site rich RNAs [26]—they affect the 
expression of thousands of genes and have the potential to synergistically dysregulate 
drivers of tumorigenesis in multiple tumor contexts.  
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Figures 
Figure 1. Model and validation of miRNA-target coupling. (A) RNAs up and down 
regulate one another by titrating shared miRNA regulators. Up regulation of RNA B 
sequesters shared miRNAs, leading to weaker miRNA-mediated repression of RNA A 
transcripts. (B) In order to validate predicted interaction networks on a large scale, we 
evaluated whether interactions are predictive of global mRNA expression changes 
following shRNA perturbations using LINCS. A selection of known cancer genes in 
breast cancer and (C) prostate adenocarcinomas were effectively repressed following 
silencing of their predicted ceRNA regulators in MCF7 and PC3, respectively. Red bars 
represent average fold changes of a target ceRNA relative to non-targeting controls 
(gray bars) following silencing of its predicted ceRNA regulators at select time points; 
see Figures 2-3 for details. Data are represented as mean ± SEM. 
Figure 2. Target response to perturbations of both predicted ceRNA regulators 
and non-regulators in MCF7. For each ceRNA target described in Figure 1B, we plot 
responses to shRNA-mediated silencing of (A) predicted ceRNA regulators and (B) 
genes not predicted to regulate each ceRNA target in MCF7. Each plot gives the 
profiling time point after shRNA transfection, and the total number of shRNA targets 
considered. For silencing of regulators, we provide p values that describe the 
significance of target responses shown in panel A relative to the response to silencing 
of other genes shown in panel B. Also provided, adjunct to each scatter plot, are box 
plots that describe the mean, median, 25 and 75 percentile of the distributions of ranks 
of the responses of this target relative to all profiled responses to shRNA perturbations. 
Figure 3. Target response to perturbations of both predicted ceRNA regulators 
and non-regulators in PC3. Analogous to Figure 2, for each ceRNA target described in 
Figure 1C, we plot responses to shRNA-mediated silencing of (A) predicted ceRNA 
regulators and (B) genes not predicted to regulate each ceRNA target in PRAD. 
Figure 4. Statistical evaluation. We plot p-values and average fold changes of target 
ceRNA expression following silencing of their predicted regulators, compared to 
silencing of all other genes in both BRCA and PRAD ceRNETs, at two profiling time 
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points in (A) MCF7 and (B) PC3 cells. Results for targets with six or more perturbed 
ceRNA regulators are shown. To estimate p values for each ceRNA target, we collected 
all tested regulators and compared average fold-change responses following silencing 
of inferred ceRNA regulators (FCpos) vs. silencing of all other genes (FCneg) in the 
network; see Figures 1-3 for illustrative example cancer genes. In total, 91% and 92% 
(50% and 47% significantly, at p < 0.05 by U test) of ceRNA targets, predicted in breast 
and prostate cancer, were down regulated in response to ceRNA regulator silencing in 
MCF7 and PC3, respectively. In total, 342 tested ceRNA targets were significantly 
down-regulated and none were significantly up-regulated. Comparing the number of 
targets with significantly low FCpos and FCneg fold changes by Mann-Whitney U-test 
suggests an FDR < 0.01 for overall network validation. 
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Supplementary Figures 
Figures S1. Accounting for systematic biases. To ensure that comparisons of target 
responses to predicted regulators and non-regulators are free of bias, we repeated the 
analysis presented in Figure 4 after controlling for several properties. The tables 
demonstrate that all results, before and after controlling for the following variables were 
in agreement: (1) ceRNA interactions associated with the most significant ceRNA-
validating responses; (2) shRNAs that can act as human miRNAs and produce off-
target effects; (3) 3’ UTR length; (4) 3’ UTR CG content; (5) RMA-normalized 
expression; (6) expression variability; and (7) expression correlation with the predicted 
target. Here we present comparisons to results presented in Figure 1. The number of 
predicted targets that were significantly (p<0.05) down regulated in response to 
transfections of shRNAs designed to target regulators are in red; down regulated 
(p>0.05) in orange; up regulated (p>0.05) in blue, and significantly up regulated 
(p<0.05) in green. P values give the confidence that the resulting distribution is not due 
to chance. 
Figure S2. The effect of predicted PTEN ceRNA regulators by each of the three 
methods. Average PTEN mRNA fold change following shRNA-mediated silencing of its 
predicted regulators, as predicted by each ceRNA inference method including random 
assay selection, and inferences by Hermes, MuTaME, and cefinder. P values were 
calculated by comparing fold changes to random assay selection with PTEN expression 
profiling, using the Student’s T-test (two-tailed). Average fold changes were normalized 
to the random assay selection. Bars show standard errors; * stands for p<0.05; ** for 
p<0.01; *** for p<0.001. 
Figure S3. Genome wide comparison. FC comparison between Hermes, cefinder and 
random assay selection. Both Hermes and cefinder significantly outperform Random. 
Hermes outperforms cefinder at P < 5E-07 and P < 2E-44, for MCF7 and PC3, 
respectively; p-values based on two-sample Kolmogorov–Smirnov tests of ceRNA-
target fold changes.  
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Supplementary Tables 
Tables S1-S2. Inferred ceRNA networks. Predicted interactions in the two tumor 
contexts: Table S1 for BRCA, and Table S2 for PRAD. Each table describes the 
coupled ceRNA pair, confidence level in the interaction, number of mediating miRNAs, 
and the identity of miRNA mediators. 
Tables S3-4. MCF7 and PC3 LINCS fold changes, describing gene-expression 
responses to perturbagens. For each LINCS gene profiled at a given time point after 
each perturbation, we provide the number of replicates (Luminex plates), observed fold 
change relative to control, and the standard error across plates. 
Table S5. BRCA and PRAD ceRNET validation using LINCS data. For each LINCS 
gene profiled at a given time point, we list (1) the number of predicted regulators that 
were silenced, (2) the size of the control set, which includes the gene’s profiling after 
shRNA-mediated silencing of genes that were not predicted to target it, (3) observed 
and expected U-statistics, (4) and Z-statistics and associated the p-values obtained 
from them. For each interaction at a given time point, we list the target fold change in 
response to the perturbation, and the percentile rank when comparing target fold 
changes to fold changes of all other profiled genes in response to the perturbation. We 
also provide the identity of shRNA hairpins used. 
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